ClinicalTrials.gg
RecruitingNCT06719063NEGLISENSUpdated May 11, 2025

Effect of Immersive Virtual Reality With Multisensory Stimulation on the Functional Impact of Hemineglect Secondary to a Right-Sided Stroke

An interventional study of Multisensory Virtual Reality in Stroke, Hemineglect and Neuropsychology, sponsored by Hopital La Musse. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-11.

Sponsored by Hopital La Musse · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 545 studies in Stroke with a site in France — 142 open to participants now, 161 under way, 12 of them phase 3. Stroke · France.

Planned enrollment
357th of 370
3 · median 64
Started
2025
with 38 others
No phase
277 of 545
93 open now
Primary completion
2025-06
later than 20 of 160 live
Registered
482nd of 545
by date

Among the 545 studies in Stroke with a site in France, this one is the 357th largest by planned enrollment of the 370 interventional ones that give a count, is one of 39 that started in 2025, is one of 277 with no phase, reaches primary completion later than 20 of the 160 other live ones, and was the 482nd registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

142 of the 545 studies in Stroke with a site in France are open now. Recruiting first, the newest first:

137 more — sign in →

All 142 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 545 studies in Stroke with a site in France, or all of them as a file.
02

Study summary

A stroke is a common and potentially serious condition that affects 130,000 people each year in France. It is the second leading cause of major cognitive disorders after Alzheimer's disease.

Hemineglect is a frequently observed cognitive impairment following a stroke. The individual becomes unable to orient themselves or respond to stimuli appearing in the contralesional hemispace. Hemineglect occurs in approximately 25-30% of stroke patients, with the right hemisphere being affected in 90% of cases.

Despite potential spontaneous recovery within the first 2 to 3 months post-stroke, neglect tends to persist chronically. One-third of patients suffer from long-term neglect. The condition is more severe after a right-sided lesion. The functional impact is significant, particularly when considering the anosognosia and anosodiaphoria often associated with it. Rehabilitation stays are longer for patients with neglect, and autonomy in daily activities is reduced. Neglect leads to poorer functional outcomes after a stroke, making it a critical factor to address in a patient's rehabilitation program.

The goal of rehabilitation is to reduce impairments, improve activity limitations and participation restrictions secondary to hemineglect, and achieve functional progress beyond what is possible through spontaneous recovery. Since no single rehabilitation method for neglect is superior to another, it is currently recommended to combine multiple approaches.

The top-down approach is based on intention and conscious effort. This technique is among the first used for neglect rehabilitation and remains widely used today. The goal is to help the patient become aware of their neglectful behavior.

The bottom-up approach relies on more automatic mechanisms of action and aims to modulate the spatial reference system through passive sensory manipulations or visuomotor adaptation.

The use of virtual reality in stroke rehabilitation promotes plasticity and neural reorganization. In the field of hemineglect, several studies have examined the effects of virtual reality using top-down and/or bottom-up approaches and have shown significant functional improvements. In the case of multisensory stimulation, delivering different stimuli to the same side of space and at the same time increases neuronal activity, leading to a stronger clinical response than unisensory stimulation.

The VirtySens® multisensory travel capsule is an immersive virtual reality technique. This total immersion is achieved through the simultaneous stimulation of four out of the five senses. Firstly, vision and hearing are stimulated by a virtual reality headset that projects high-definition films. Smell is activated through the release of micro-droplets of fragrances synchronized with the imagery. Finally, touch is stimulated by warm and cold airflows that enhance the various scenes presented.

The investigators emit the hypothesis that the VirtySens® capsule, immersive virtual reality combining multisensory stimulation via four of the five senses and training in visual scanning, introduced in rehabilitation, allows to significantly reduce the functional impact of hemineglect in the adult victim of a right cerebral infarction dating less than 3 months.

To respond to these research objectives, the investigators will carry out a pilot study in Single Case Experimental Design (SCED). The experimentation will take place in mainland France within La Musse hospital. The recruitment of 3 subjects will be necessary for the realization of this study.

The study will consist of repeated evaluation and rehabilitation sessions. Evaluations will be conducted at La Musse Hospital by an occupational therapist. The purpose of the evaluation sessions is to measure the impact of hemineglect on autonomy. This measurement will be performed using the Catherine Bergego Scale, which will be completed by both the patient and the occupational therapist. Evaluation sessions will last approximately 45 minutes and will take place once a week for 10 to 12 weeks.

After 3 to 5 weeks of evaluations, the patient will participate in three weekly rehabilitation sessions, each lasting 45 minutes, over a 5-week period. These sessions will be individual and conducted by an occupational therapist. Each session will follow a similar structure: review of the previous session, explanation of the current session, a 15-minute multisensory experience using virtual reality, followed by a review of the session, particularly focusing on tolerance.

03

Conditions studied

  • Stroke
  • Hemineglect
  • Neuropsychology
  • Virtual Reality
  • Rehabilitation
  • Immersion

Browse trials for

Keywords

  • stroke
  • hemineglect
  • neuropsychology
  • virtual reality
  • rehabilitation
  • multisensory
  • immersion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient aged over 18 years
  • Diagnosis of first ischemic right stroke established by a neurologist using clinical examination and brain imaging (CT scan or MRI)
  • Stroke occurring less than 3 months ago
  • Presence of left hemineglect, diagnosed using the Neglect Assessment Battery (NAB)
  • Normal vision or corrected to normal
  • Patient affiliated with the social security system

Exclusion criteria

Exclusion Criteria:

  • History of neurological or psychiatric illness
  • Epilepsy
  • Craniotomy
  • Limited range of cervical motion due to orthopedic disorders
  • Moderate or severe deafness (hearing loss of 40 dB in one ear, as measured by tonal audiometry)
  • Anosmia (loss of smell)
  • Asthmatic disease
  • Pregnant women or women suspected of being pregnant
  • Breastfeeding women
  • Severe neurocognitive disorders with an score \< 21
  • Patient under legal protection measures
  • Minor patient
  • Patient enrolled in another research protocol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (estimated)

Study arms

  • Experimental
    Experimental

    The evaluation sessions aim to measure the impact of hemineglect on autonomy. This measurement will be conducted using the Catherine Bergego Scale, which will be completed by both the patient and the occupational therapist. Evaluation sessions will last approximately 45 minutes and will take place once a week for 10 to 12 weeks. After 3 to 5 weeks of evaluations (Phase A: baseline), the patient will participate in three weekly rehabilitation sessions, each lasting 45 minutes, over a 5-week period (Phase B: therapy). These sessions will be individual and conducted by an occupational therapist. Each session will follow a similar structure: review of the previous session, explanation of the current session, a 15-minute multisensory experience using virtual reality, and a final review focusing particularly on tolerance. A multisensory experience has been specifically designed for the rehabilitation protocol. The experience consists of two 360° nature-themed films. Throughout the experie

    Other: Multisensory Virtual Reality

Interventions

  • OtherMultisensory Virtual Reality

    The VirtySens® multisensory travel capsule is an immersive virtual reality technique. This total immersion occurs through the simultaneous stimulation of four of the five senses. Session duration: 45 minutes, with 15 minutes dedicated to the protocol administration. The remaining 30 minutes will be used to welcome the patient, explain the content of the session, and review the session's outcome, particularly to assess tolerance (Simulator Sickness Questionnaire (SSQ) completed at the start of each week after the first VirtySens® session). The sessions will take place in the morning to prevent the session from being disrupted by fatigue related to the rehabilitation day.

06

What researchers measure

Primary outcomes

  1. The impact of hemineglect on autonomy

    The evaluation sessions aim to measure the impact of hemineglect on autonomy. This measurement will be conducted using the Catherine Bergego Scale, which will be completed by both the patient and the occupational therapist. This scale is scored from 0 to 30 points; the higher the score, the more severe the behavioural neglect.

    Time frame: From study enrollment, up to 12 weeks, every 7 days

Secondary outcomes

  1. The measurement of anosognosia or awareness of hemineglect

    The measurement of anosognosia or awareness of hemineglect in an ecological setting, using the Catherine Bergego Scale. This scale is scored from 0 to 30 points; the higher the score, the more severe the behavioural neglect.

    Time frame: From study enrollment, up to 12 weeks, every 7 days

  2. The measurement of tolerance to immersive virtual reality

    The measurement of tolerance to immersive virtual reality, combining multisensory stimulation through four of the five senses and visual scanning training, introduced in rehabilitation, using the Simulator Sickness Questionnaire. This scale is scored from 0 to 48 points, the higher the score, the greater the cybermalaise.

    Time frame: From study enrollment, up to 12 weeks, every 7 days

07

Study locations

1 of 1 sites recruiting
  • Hôpital La Musse
    Saint-Sébastien-de-Morsent, 27180, France
    Recruiting
    • Héloïse BAILLET, PhD · Contacth.baillet@hlrs-lamusse.net · +33(0)232293047
    • Julie LE BALC'H · Contactj.lebalch@hlrs-lamusse.net · +33(0)232293001
    • Héloïse BAILLET, PhD · Principal investigator
    • Audrey BRINGER, Dr, MsC · Sub investigator
    • Marie-Sophie HERVIEU-BIDAULT, Dr · Sub investigator
    • Gilles LE DIBERDER · Sub investigator
    • Capucine HENNEQUIN · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jun 2025, 2 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 2 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2024
First posted
Dec 5, 2024
StartActual
Apr 4, 2025
Primary completionEst.
Jun 15, 2025
CompletionEst.
Aug 31, 2025
Last update
May 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06719063
Lead sponsor
Hopital La Musse
Responsible party
Sponsor
First posted
Dec 5, 2024
Start date
Apr 4, 2025
Primary completion
Jun 15, 2025 (estimated)
Completion
Aug 31, 2025 (estimated)
Last update
May 11, 2025

Study contacts

Héloïse BAILLET, PhD
Contact
h.baillet@hlrs-lamusse.net
+33(0)232293047
Julie LE BALC'H
Contact
j.lebalch@hlrs-lamusse.net
+33(0)232293001

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion